CHITOSE-BIO-EVOLUTION
14.9.2023 15:01:36 CEST | Business Wire | Press release
CHITOSE BIO EVOLUTION PTE. LTD., the leader of the global bioeconomy and the headquarters of the CHITOSE Group (hereinafter "CHITOSE"), has successfully concluded a total of 21M USD new share issuances through a third-party allotment with Shiseido Company, Limited, NGK INSULATORS, LTD., Mitsui Mining & Smelting Co. Ltd. (*1), Mitsubishi Kakoki Kaisha.Ltd., Amano Enzyme Inc., Mers Line Pte. Ltd. (*2), Ikeda tohka Industries Co., Ltd. and SHINSHO CORPORATION. The funds raised will be allocated towards the expansion of the microalgae production facility and R&D of product applications in order to accelerate MATSURI, the project to build a microalgae-based industry to replace the petroleum industry. Through these commitments, CHITOSE will contribute to the realization of zero carbon emissions and work together with others toward a prosperous future that will last beyond a thousand years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230914666208/en/
Microalgae Production Scale Roadmap (Graphic: Business Wire)
*1 Investment by Mitsui Kinzoku-SBI Material Innovation Fund with Mitsui Mining & Smelting Co. Ltd. as a Limited Partnership and SBI Investment as a General Partnership.
*2 Investment by Sun Sail Navigation Pte. Ltd., which belongs to the Mers Line Pte Ltd. group.
Rationale for the Capital Increase & Use of Proceeds
CHITOSE envisions a future in which humankind can live prosperously for the next thousand years and aims to build an unprecedented microalgae-derived industry. Working in collaboration with progressive companies and organizations spanning various sectors and industries, CHITOSE is simultaneously expanding the scale of production and developing multifaceted applications in order to promote the use of microalgae products in fuels, foods, chemical products, cosmetics, and feedstuffs that support people's lives.
In terms of scale-up of microalgae production facilities, following completion of a 0.1 hectare facility in August 2018, CHITOSE successfully inaugurated a 5 hectare-facility named CHITOSE Carbon Capture Central (C4) in April 2023. CHITOSE plans to expand it further to a scale of 2,000 hectares by 2030 and 10 million hectares by 2050. In the current fiscal year, CHITOSE has just launched the 2,000 hectare-project, of which the initial 100 hectare-facility development along with the R&D of various applications have been selected as a commissioned project by the Green Innovation Fund / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material (*3) of NEDO (*4).
*3 About the Green Innovation Fund Project / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material
https://green-innovation.nedo.go.jp/en/project/bio-manufacturing-technology/
*4 New Energy and Industrial Technology Development Organization
Future Procurement Plans
Growing expectations for stable procurement of resources and contribution to sustainable manufacturing enabled us to achieve our target of 20M USD for the current fiscal year during the first half of the year. Responding to strong market demand, CHITOSE intends to continue vigorous dialogue with investors in the second half of the year and beyond.
*Note: All figures are the exchange value of the USD calculated as of September 8, 2023.
Stakeholder’s Comments
Shiseido Company, Limited
"Under our mission of 'BEAUTY INNOVATIONS FOR A BETTER WORLD,' our company is committed to developing cosmetics that are not only good for the skin, but also promotes a healthy and beautiful natural environment. We are working with the CHITOSE Group to build a circular model, maximizing the potential of 'algae,' and integrating it into the earth's system, ensuring resources are not depleted. We will lead the creation of sustainable value, thereby revitalizing the global cosmetics market."
NGK INSULATORS, LTD.
"NGK, a member of MATSURI, is encouraged to develop algae business that contributes to carbon neutrality with our unique ceramic technologies. NGK and CHITOSE Group will extend our collaboration to realize social implementation of the bio industry."
Mitsui Mining & Smelting Co., Ltd.
"Mitsui Mining & Smelting Co., Ltd. is working to co-create a value chain for bio-manufacturing by applying our unique catalyst, separation and purification technologies in order to contribute to the realization of a sustainable society."
Mitsubishi Kakoki Kaisha, Ltd.
"Mitsubishi Kakoki Kaisha believes that algae can be a solution to the global food and energy problems, and this investment is in line with our long-term management vision. We will work closely with the MATSURI project and contribute to the development of the algae business with our technology."
Mers Line Pte. Ltd.
"With the utilization of microalgae, a carbon-free society is just around the corner. We sympathize with the philosophy of CHITOSE Group, 'To live in abundance beyond the next millennium using the ability of living things' and support their activities."
Ikeda tohka Industries Co.,Ltd.
"As a food ingredient manufacturer with over 100 years of history, we harness our cultivated food processing technology to convert algae biomass into a usable form for industries. Through this, we support the creation of a sustainable and carbon-neutral society."
SHINSHO CORPORATION
"Through this investment, we intend to collaborate with CHITOSE Group, in order to build a new resource-recycling business model through carbon recycling and new business development using microalgae."
###
About MATSURI
https://matsuri-partners.chitose-bio.com/en
The MATSURI project aims towards the establishment of an advanced microalgae-based industry. CHITOSE has considerable expertise in large-scale photosynthetic production technologies, and is leading the MATSURI project collaborating with Japanese progressive enterprises. As what MATSURI means in Japanese, CHITOSE keeps leading a festival to develop a sustainable society. If you are interested in MATSURI, please feel free to contact the MATSURI office. Click here to contact us.
Related Information
[Press Release] CHITOSE Group, Successfully Concludes Capital Increase of 7M USD Scale from Shiseido and Forms Strategic Partnership ― Accelerate a Microalgae-based Circular Manufacturing in a Cosmetic Industry —
[Press Release] CHITOSE Group Obtains Funding from Japanese Government(NEDO) for Green Innovation Fund of 400M USD Scale
[MATSURI partner site] Shiseido Company, Limited Joined MATSURI as a Corporate Partner (Japanese)
[MATSURI partner site] Amano Enzyme Inc. Joined MATSURI as an Industry Restructuring Partner (Japanese)
CHITOSE Group Overview
https://chitose-bio.com/
CHITOSE Group is a family of biotechnology companies leading the global bioeconomy. To live in abundance beyond the next millennium using the ability of living things, CHITOSE pursues the possibilities of biotechnology through technological and business development collaborating with its business partners all over the world.
About CHITOSE BIO EVOLUTION PTE. LTD. (head office that oversees entire Group)
Established in October, 2011
Head Office located in Singapore
CEO: Tomohiro FUJITA, Ph. D.
About CHITOSE Laboratory Corp. (responsible for the project)
Established in November, 2002
Head Office located in Kanagawa Prefecture, Japan
CEO: Tomohiro FUJITA, Ph. D.
COO: Rie KUGIMIYA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914666208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom